Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers
January 08 2018 - 8:00AM
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace”
or the “Company”), a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for improved patient diagnosis and management announced today that
CIO Applications, a publication that is known to offer
professionals a comprehensive collection of industry trends, has
designated Interpace Diagnostics as one of the top 20 Companies in
2017 for providing bioinformatics solutions to their customers thru
the Company’s extensive database of molecular testing
results.
The December 2017 edition of CIO Applications notes, “The list
highlights some of the most prominent organizations in the industry
who are competent in leading their clients toward excellence by
offering innovative solutions in the Bioinformatics landscape.”
In addition to Interpace, the top 20 companies include Roche
Sequencing Solutions, Qiagen, Precision Medicine Group, Illumina,
and AltheaDX. The rising applications of bioinformatics
in drug discovery, development, and clinical trials are believed to
be contributing to the growth of the bioinformatics market.
As noted in the article, “Interpace’s databases contain
molecular testing results along with numerous other data elements
for thousands of patients across a wide array of cancer types
including Pancreatic, Thyroid, Esophageal, and Lung.” One
example is the National Pancreatic Cyst Registry, one of the
largest databases of molecular data on patients with suspicious
pancreatic cancer. According to CIO Applications, “the list
aspires to assist individuals and companies to find the right
bioinformatics solutions provider that meets their specific
requirements and assist them in completing their
projects.”
The full article can be found at:
https://www.cioapplications.com/vendors/top-20-bioinformatics-solution-providers-2017-rid-64.html
According to Jack Stover, President and CEO of Interpace, “We
are pleased to be recognized by CIO Applications for our ability to
deliver bioinformatics solutions to our current customers as well
as potentially to other organizations who find value in our
substantial expertise in high throughput DNA analysis and our
extensive databases of patient results and other important
data. We believe that this publication further validates the
value of our growing database of over 45,000 patients who have been
tested with our current products. We look forward to further
developing and expanding this bioinformatics opportunity in the
pharmaceutical sector and elsewhere in 2018 and beyond.”
About Interpace Diagnostics Group,
Inc.
Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for improved patient diagnosis and management. The Company
currently has four commercialized molecular tests and one test in a
clinical evaluation process (CEP): PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for
the diagnosis of thyroid cancer from thyroid nodules utilizing a
next generation sequencing assay; ThyraMIR®, for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDX™ that differentiates lung cancer of
primary vs. metastatic origin. BarreGEN® for Barrett's
Esophagus, is currently being “soft launched” with key opinion
leaders as we continue to gather data on this assay that will
assist us in seeking favorable reimbursement as well as important
clinical information. Barrett's Esophagus is a rapidly growing
diagnosis that affects over three million people in the US and over
time can progress to esophageal cancer. The Company’s database
includes data from over 45,000 patients who have been tested using
the Company’s current products, including over 15,000 molecular
tests for thyroid nodules. Interpace has been designated as one of
the top 20 companies for providing bioinformatics solutions.
Interpace’s mission is to provide personalized medicine
through molecular diagnostics, innovation and data to advance
patient care based on rigorous science. For more information,
please visit Interpace’s website
at www.interpacediagnostics.com
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, relating to the Company's
future financial and operating performance. The Company has
attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to, the Company's ability to adequately finance the
business, the market's acceptance of its molecular diagnostic
tests, its ability to retain or secure reimbursement, its ability
to secure additional business and generate higher profit margins
through sales of its molecular diagnostic tests, in-licensing or
other means, projections of future revenues, growth, gross profit
and anticipated internal rate of return on investments and its
ability to maintain its NASDAQ listing. Additionally, all
forward-looking statements are subject to the “Risk Factors”
detailed from time to time in the Company's most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q and other
SEC filings.
Because of these and other risks, uncertainties and assumptions,
undue reliance should not be placed on these forward-looking
statements. In addition, these statements speak only as of the date
of this press release and, except as may be required by law, the
Company undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:
Interpace Diagnostics Investor Relations:
Paul Kuntz Redchip Paul@Redchip.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024